IL133535A0 - Method for inhibiting bone resorption - Google Patents
Method for inhibiting bone resorptionInfo
- Publication number
- IL133535A0 IL133535A0 IL13353598A IL13353598A IL133535A0 IL 133535 A0 IL133535 A0 IL 133535A0 IL 13353598 A IL13353598 A IL 13353598A IL 13353598 A IL13353598 A IL 13353598A IL 133535 A0 IL133535 A0 IL 133535A0
- Authority
- IL
- Israel
- Prior art keywords
- bone resorption
- disclosed
- inhibiting bone
- methods
- etridronate
- Prior art date
Links
- 208000006386 Bone Resorption Diseases 0.000 title abstract 2
- 230000024279 bone resorption Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- -1 etridronate Chemical compound 0.000 abstract 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 abstract 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 229940062527 alendronate Drugs 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 abstract 1
- 229960002286 clodronic acid Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
- 229940015872 ibandronate Drugs 0.000 abstract 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 abstract 1
- 229950006971 incadronic acid Drugs 0.000 abstract 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 abstract 1
- 229940046231 pamidronate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940089617 risedronate Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229940019375 tiludronate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
- Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
- Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL14121898A IL141218A0 (en) | 1997-07-22 | 1998-07-17 | Alendronic acid, pharmaceutically acceptable salts thereof or mixtures thereof, for use as a medicament or for use in the manufacture of a medicament, pharmaceutical compositions and kits comprising any of thereof, all for inhibiting bone resorption |
| IL14326498A IL143264A0 (en) | 1997-07-22 | 1998-07-17 | A combination of a histamine h2 receptor blocker or a proton pump inhibitor and a bisphosphonate or pharmaceutically acceptable salts thereof or mixtures thereof, for use as a medicament, for use in the manufacture of a medicament, pharmaceutical compositions and kits comprising any thereof, all for inhibiting bone resorption |
| IL15310998A IL153109A (en) | 1997-07-22 | 1998-07-17 | An effective pharmaceutical composition for inhibiting bone resorption in humans containing alendronic acid or its acceptable pharmaceutical salt or mixture |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5335197P | 1997-07-22 | 1997-07-22 | |
| US5353597P | 1997-07-23 | 1997-07-23 | |
| GBGB9717590.5A GB9717590D0 (en) | 1997-08-20 | 1997-08-20 | Oral method for treating or preventing abnormal bone resorption |
| GBGB9717850.3A GB9717850D0 (en) | 1997-08-22 | 1997-08-22 | Oral method for treating or preventing abnormal bone resorption |
| PCT/US1998/014796 WO1999004773A2 (en) | 1997-07-22 | 1998-07-17 | Method for inhibiting bone resorption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL133535A0 true IL133535A0 (en) | 2001-04-30 |
Family
ID=27451690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13353598A IL133535A0 (en) | 1997-07-22 | 1998-07-17 | Method for inhibiting bone resorption |
Country Status (31)
| Country | Link |
|---|---|
| EP (5) | EP0998292B1 (enExample) |
| JP (2) | JP3479780B2 (enExample) |
| KR (3) | KR20030097611A (enExample) |
| CN (3) | CN1602879A (enExample) |
| AT (2) | ATE357921T1 (enExample) |
| AU (1) | AU8493698A (enExample) |
| BG (1) | BG66282B1 (enExample) |
| BR (1) | BR9810779A (enExample) |
| CA (1) | CA2294595C (enExample) |
| CY (2) | CY1107535T1 (enExample) |
| DE (6) | DE122006000009I1 (enExample) |
| DK (2) | DK1175904T3 (enExample) |
| EA (1) | EA004544B2 (enExample) |
| EE (1) | EE05603B1 (enExample) |
| ES (3) | ES2253136T1 (enExample) |
| HK (4) | HK1042230A1 (enExample) |
| ID (1) | ID24096A (enExample) |
| IL (1) | IL133535A0 (enExample) |
| IS (3) | IS5315A (enExample) |
| LU (2) | LU91222I2 (enExample) |
| NL (2) | NL300223I1 (enExample) |
| NO (1) | NO20000323L (enExample) |
| NZ (1) | NZ501807A (enExample) |
| PL (1) | PL195272B1 (enExample) |
| PT (2) | PT1175904E (enExample) |
| SG (2) | SG139556A1 (enExample) |
| SI (1) | SI0998292T1 (enExample) |
| SK (1) | SK932000A3 (enExample) |
| TR (1) | TR200000145T2 (enExample) |
| UY (1) | UY25950A1 (enExample) |
| WO (1) | WO1999004773A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69916326T2 (de) * | 1998-12-25 | 2005-03-17 | Yamanouchi Pharmaceutical Co., Ltd. | Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom |
| NZ515541A (en) * | 1999-05-21 | 2003-03-28 | Novartis Ag | Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis |
| CN100349574C (zh) * | 1999-07-19 | 2007-11-21 | 东丽株式会社 | 牙周疾病用剂 |
| WO2001046040A1 (en) | 1999-12-20 | 2001-06-28 | Merck & Co., Inc. | Blister package for pharmaceutical treatment card |
| IL142515A0 (en) * | 1999-12-20 | 2002-03-10 | Merck & Co Inc | Pharmaceutical kit |
| MXPA02009924A (es) * | 2000-04-07 | 2004-08-19 | Univ Texas | Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida. |
| DE60113537T3 (de) | 2000-06-20 | 2013-05-29 | Novartis Ag | Methode zur verabreichung von biphosphonaten |
| RU2288722C2 (ru) * | 2000-06-20 | 2006-12-10 | Новартис Аг | Способ введения бисфосфонатов |
| US6638920B2 (en) * | 2000-07-21 | 2003-10-28 | Merck & Co., Inc. | Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| SE0101379D0 (sv) | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
| JP2004528365A (ja) * | 2001-05-02 | 2004-09-16 | ノバルティス アクチエンゲゼルシャフト | 骨再吸収症および骨粗しょう症の処置または予防におけるビスホスホネートの吸入投与方法 |
| DE60317061T2 (de) * | 2002-05-10 | 2008-07-24 | F. Hoffmann-La Roche Ag | Ibandronsäure zur behandlung und vorbeugung von osteoporose |
| SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
| NZ545804A (en) * | 2003-09-19 | 2009-09-25 | Wisconsin Alumni Res Found | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate |
| WO2005072747A1 (ja) * | 2004-02-02 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 骨吸収抑制剤 |
| EP1937362B1 (en) * | 2005-09-16 | 2013-03-27 | Selamine Ltd. | Bisphosphonate formulation |
| KR20170104664A (ko) * | 2010-12-06 | 2017-09-15 | 에프락스 파머슈티컬즈 소시에떼 아노님 | 신속한 용해 특성을 구비한 안정한 발포성 비스포스포네이트 제형 |
| CN106924257B (zh) * | 2017-03-14 | 2019-11-19 | 湖南赛隆药业有限公司 | 质子泵抑制剂和抗骨质疏松药的复合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84731A0 (en) * | 1986-12-19 | 1988-05-31 | Norwich Eaton Pharma | Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them |
| SE8704436D0 (sv) * | 1987-11-13 | 1987-11-13 | Pm Konsult Handelsbolag | Anvendning av antisekretoriska substanser for nya indikationer |
| ES2074769T3 (es) * | 1991-07-01 | 1995-09-16 | Gergely Gerhard | Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo. |
| CA2122479C (en) * | 1991-11-22 | 1998-08-25 | Richard John Dansereau | Risedronate delayed-release compositions |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| US5294433A (en) * | 1992-04-15 | 1994-03-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
| DK0648120T3 (da) * | 1992-06-30 | 1998-01-19 | Procter & Gamble Pharma | Anvendelse af phosphonater til behandling af osteoporose |
| US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
| JPH11506750A (ja) * | 1995-06-06 | 1999-06-15 | メルク エンド カンパニー インコーポレーテッド | 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法 |
| ATE256456T1 (de) * | 1996-05-17 | 2004-01-15 | Merck & Co Inc | Biphosphonat-formulierung mit brausewirkung |
-
1998
- 1998-07-17 BR BR9810779-8A patent/BR9810779A/pt not_active Application Discontinuation
- 1998-07-17 ES ES01201910T patent/ES2253136T1/es active Pending
- 1998-07-17 SK SK93-2000A patent/SK932000A3/sk not_active Application Discontinuation
- 1998-07-17 DE DE1998603291 patent/DE122006000009I1/de active Pending
- 1998-07-17 DE DE69803291T patent/DE69803291T2/de not_active Revoked
- 1998-07-17 PT PT01201913T patent/PT1175904E/pt unknown
- 1998-07-17 KR KR1020027013595A patent/KR20030097611A/ko not_active Ceased
- 1998-07-17 EP EP98935752A patent/EP0998292B1/en not_active Revoked
- 1998-07-17 SG SG200603406-0A patent/SG139556A1/en unknown
- 1998-07-17 ES ES01201913T patent/ES2269014T3/es not_active Expired - Lifetime
- 1998-07-17 ES ES98935752T patent/ES2164447T3/es not_active Expired - Lifetime
- 1998-07-17 DK DK01201913T patent/DK1175904T3/da active
- 1998-07-17 WO PCT/US1998/014796 patent/WO1999004773A2/en not_active Ceased
- 1998-07-17 EA EA200000151A patent/EA004544B2/ru not_active IP Right Cessation
- 1998-07-17 EP EP01201912A patent/EP1175903A3/en not_active Ceased
- 1998-07-17 EE EEP200000040A patent/EE05603B1/xx unknown
- 1998-07-17 AT AT01201913T patent/ATE357921T1/de active
- 1998-07-17 CA CA002294595A patent/CA2294595C/en not_active Expired - Fee Related
- 1998-07-17 DE DE200712000063 patent/DE122007000063I1/de active Pending
- 1998-07-17 TR TR2000/00145T patent/TR200000145T2/xx unknown
- 1998-07-17 DE DE01201911T patent/DE01201911T1/de active Pending
- 1998-07-17 DE DE01201913T patent/DE01201913T1/de active Pending
- 1998-07-17 CN CNA2004100557346A patent/CN1602879A/zh active Pending
- 1998-07-17 KR KR1020007000680A patent/KR100391732B1/ko not_active Expired - Fee Related
- 1998-07-17 KR KR1020027013594A patent/KR20030097610A/ko not_active Ceased
- 1998-07-17 PL PL98338635A patent/PL195272B1/pl unknown
- 1998-07-17 NZ NZ501807A patent/NZ501807A/en not_active IP Right Cessation
- 1998-07-17 CN CNB2004100557350A patent/CN1299689C/zh not_active Expired - Lifetime
- 1998-07-17 JP JP50991499A patent/JP3479780B2/ja not_active Expired - Lifetime
- 1998-07-17 ID IDW20000114A patent/ID24096A/id unknown
- 1998-07-17 EP EP01201910A patent/EP1132088A3/en not_active Ceased
- 1998-07-17 IL IL13353598A patent/IL133535A0/xx unknown
- 1998-07-17 AT AT98935752T patent/ATE209037T1/de active
- 1998-07-17 PT PT98935752T patent/PT998292E/pt unknown
- 1998-07-17 SG SG200107221A patent/SG109478A1/en unknown
- 1998-07-17 AU AU84936/98A patent/AU8493698A/en not_active Abandoned
- 1998-07-17 SI SI9830086T patent/SI0998292T1/xx unknown
- 1998-07-17 EP EP01201913A patent/EP1175904B8/en not_active Revoked
- 1998-07-17 EP EP01201911A patent/EP1151752A3/en not_active Ceased
- 1998-07-17 DK DK98935752T patent/DK0998292T3/da active
- 1998-07-17 CN CNB988074737A patent/CN1166365C/zh not_active Ceased
- 1998-07-17 DE DE69837450T patent/DE69837450T2/de not_active Expired - Lifetime
-
1999
- 1999-12-21 IS IS5315A patent/IS5315A/is unknown
-
2000
- 2000-01-17 UY UY25950A patent/UY25950A1/es not_active Application Discontinuation
- 2000-01-18 BG BG104093A patent/BG66282B1/bg unknown
- 2000-01-21 NO NO20000323A patent/NO20000323L/no unknown
-
2002
- 2002-03-04 HK HK02101656.1A patent/HK1042230A1/en unknown
- 2002-03-12 HK HK02101869.4A patent/HK1042232A1/en unknown
- 2002-03-16 HK HK02102043.1A patent/HK1040495A1/en unknown
- 2002-03-16 HK HK02102042.2A patent/HK1040494A1/en unknown
-
2003
- 2003-03-10 JP JP2003063378A patent/JP2005068010A/ja active Pending
-
2004
- 2004-04-21 IS IS7230A patent/IS7230A/is unknown
- 2004-04-21 IS IS7231A patent/IS7231A/is unknown
-
2006
- 2006-02-07 NL NL300223C patent/NL300223I1/nl unknown
- 2006-02-15 LU LU91222C patent/LU91222I2/fr unknown
-
2007
- 2007-03-29 CY CY20071100442T patent/CY1107535T1/el unknown
- 2007-09-12 LU LU91364C patent/LU91364I2/fr unknown
- 2007-09-13 NL NL300292C patent/NL300292I1/nl unknown
- 2007-09-20 CY CY2007022C patent/CY2007022I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU91364I2 (fr) | Alendronate de sodium /colécalciférol | |
| NZ272608A (en) | Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts | |
| HRP20020594B1 (en) | Pharmaceutical parenteral composition containing a biphosphonate | |
| NZ545804A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate | |
| YU1800A (sh) | Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju | |
| BR9609477A (pt) | Composto composição farmacêutica e processos para preparação de tiludronato dissódico e para obtenção de uma composição farmacêutica | |
| PE120399A1 (es) | Composiciones que inhiben la resorcion osea | |
| TWI226833B (en) | Pharmaceutical composition for inhibiting bone resorption | |
| MX9709906A (es) | Uso de bisfosfonatos para preparar composiciones para prevenir perdida de hueso asociada con terapia inmunosupresora. |